Purification and Characterization of Anti-complementary Polysaccharides from Teucrium viscidum

Jin Gi MIN^1,

¹Department of Food Science and Technology, Pukyong National University, Daeyeon 3-dong, Nam-gu, Busan 608-737, Korea

Cite this paper:
Jin Gi MIN. Purification and Characterization of Anti-complementary Polysaccharides from Teucrium viscidum. Journal of Food and Nutrition Research. 2017; 5(6):399-405. doi: 10.12691/jfnr-5-6-6

Abstract

The anti-complementary activities of aqueous polysaccharides from Teucrium viscidum and their inhibitory effects on the complement system were examined. TM4a, a polysaccharide purified by Sepharose CL-6B, showed significant anti-complementary activities on the classical, alternative and lectin pathways. The predominant linkages of TM4a consisted of 3.1 mol of 4-O-linked galactose, 2.8 mol of 3-O-linked galactose and 2.1 mol of 4-O-linked glucose; the branched polysaccharide was also indicated by the presence of 3,6-O-linked and 2,6-O-linked glucose. The inhibitory effects of TM4a and heparin showed similar results with regard to all complement pathways, except at the concentration of 100 μg/mL. After blocking the complement components with TM4a (620 μg/mL), C3 component, C3-deficient serum, or C3-deficient serum with a C3 component were added to the mixture. Hemolysis of the mixture with the C3 component, or C3-deficient serum showed about 18% or 21% hemolysis of EA cell, while the mixture with the C3-deficient serum containing C3 showed an increase in the hemolysis of EA cells of 68% with regard to the classical pathway. Regarding the alternative pathway, C3 component with TM4a was not cleaved into C3b and C3a during electrophoresis.

Keywords:
complement anti-complementary polysaccharide

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Walport, M.J., Complement First of two parts. N Engl. J. Med., 344, 1058-1066, 2001.
[2]	Carroll, M.C., “The complement system in regulation of adaptative immunity,” Nature Immunology, 5, 981-986, 2004.
[3]	Muller-Eberhard, H.J., “The membrane attack complex of complement,” Annu Rev Immunol., 5, 503-506, 1986.
[4]	Morgan, B.P. and Walport, M.J., “Complement deficiency and disease,” Immunol. Today, 12, 301-306, 1991.
[5]	Kozlov, L.V., Burdelev, O.O., Bureeva, S.V. and Kaplun, A.P., “Artificial inhibition of the complement system,” Russian journal of bioorganic chemistry, 33, 449-473, 2007.
[6]	Volanakis, J. E. and Arlaud, G. J., “in The Human Complement System in Health and Disease (Frank, M., and Volanakis, J. E., eds),” Marcel-Dekker, New York, 49-81, 1998.
[7]	Sahu, A., Morikis, D. and Lambris, J.D., “Complement inhibitors targeting C3, C4, and C5; in Therapeutic interventions in the complement system (eds),” 75-112, 2000.
[8]	Markiewski, M.M. and Lambris, J.D., “The role of complement in inflammatory diseases from behind the scenes into the spotlight,” Am. J. Pathol., 171, 715-727, 2007.
[9]	Kiyohara, H. anf Yamada, H., “Structure of an anti-complementary arabinogalactan from the root of Angelica acutiloba Kitagawa,” Carbohydrate Res., 193, 193-200, 1989.
[10]	Yamada, H., Otsuka, Y. and Omura, S., “Structural characterization of anti-complementary polysaccharides from the leaves of Artemisiae princeps,” Planta medica, 52, 311-320, 1986.
[11]	Han, X., Zhang, Y., Zhang, J. and Chen, D., “Isolation and characterization of anti-complementary polysaccharide D3-S1 from the roots of Bupleurum smithii,” Int. J. Immunopharmacol., 7, 175-182, 2007.
[12]	Min, J.G., Kim, T.J., Lee, D.S., Cho. S.W., Yoon, H.D. and Park, J.H., “Characterization of anti-complementary polysaccharide from Teucrium viscidum,” J. Food Sci. Nutr., 6, 137-141, 2001.
[13]	Dubios, M., Gilles, K.A., Hamilton, J.K., Rebers, P.A. and Smith, F., “Colorimetric method for determinaton of sugars and related ubstances,” Analyt. Chem., 28, 250-256, 1956.
[14]	Blumenkrantz, N. and Asboe-Hansen, G., “New method for quantitative determination of uronic acids,” Analyt. Biochem., 54, 484-489, 1973.
[15]	Yamada, H., Ra, K.S., Kiyohara, H., Cyong, J.C., Yang, H.C. and Otuka, Y., “Characterization of anti-complementary neutral polysaccharides from the roots of Bupleurum facatum,” Phytochemistry, 27, 3163-3169, 1988.
[16]	Chaplin, M.F., “A rapid and sensitive method for the analysis of carbohydrate components in glycoproteins using gas-liquid chromatography,” Analyt. Biochem., 123, 336-340, 1982.
[17]	Hakomori, S.I., “A rapid permethylation of glycolipid, and polysaccharide catalyzed by methylsulfinylcarbanion in dimethylsulfoxide,” J. Biochem. (Tokyo), 55, 205-208, 1964.
[18]	Kaba, E.A. and Mayer, M.M., “Complement and complement fixation, Experimental Immuno -chemistry.” Charles C Thomas publisher, Illinois, 133, 1964.
[19]	Law, S.K. and Reid, K.B.M., “Complement, in Focus Series(2ed),” D. Male, Ed. IRL Press, Oxford, UK, 66-71, 1995.
[20]	Makrides, S.C., “Therapeutic inhibition of the complement system,” Pharmacol. Rev., 50, 59-87, 1988.
[21]	Pugsley, M.K., Abramova, M., Cole, T., Yang, X. and Ammons W.S., “Inhibitors of the complement system currently in development for cardiovascular disease,” Cardiovascular Toxicology, 3, 43-69, 2003.
[22]	Wetsel, R.A., Kildsgaard, J. and Haviland, D.L., “Complement anaphylatoxins (C3a, C4a, C5a) and their receptors (C3aR, C5aR/CD88) as therapeutic targets in inflammation,” Humana Press, pp 113-153, 2000.
[23]	Ehrengruber, M.U., Geiser, T. and Deranleau, D.A., “Activation of human neutrophils by C3a and C5A: comparison of the effects on shape changes, chemotaxis, secretion, and respiratory burst,” FEBS Lett. 346,181-184, 1994.
[24]	Fukuoka, Y. and Hugli, T.E., “Demonstration of a specific C3a receptor on guinea pig Platelets,” J. Immunol., 140, 3496-3501, 1988.
[25]	Haviland, D.L., McCoy, R.L., Whitehead, W.T., Akama, H., Molmenti, E.P., Brown, A., Haviland, J.C., Parks, W.C., Perlmutter, D.H. and Wetsel, R.A., “Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung,” J. Immunol., 154, 1861-1869, 1955.
[26]	Schwaeble, W.J., Dahl, M.R., Thiel, S., Stover, C.M. and Jensenius, J.C., “The mannan-binding lectin-associated serine proteases (MASPs) and Map19: four components of the lectin pathway activation complex encoded by two genes,” Immunobiology, 205, 455-466, 2002.
[27]	Thiel, S., Vorup-Jensen, T., Stover, C.M., Schwaeble, W., Laursen, S.B., Poulsen, K., Willis, A,C., Eggleton, P., Hansen, S., Holmskov, U., Reid, K.B.M. and Jensenius, J.C., “A second serine protease associated with mannan-binding lectin that activates complement,” Nature, 386, 506-509, 1997.
[28]	Pangburn, M.K. and Müller-Eberhard, H.J., “Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3,” Ann. N Y. Acad. Sci., 421, 291-298, 1983.
[29]	Ecker, E.E. and Gross, P., “Anticomplementary power of heparin,” J. Infect. Dis., 44, 250-253, 1929.
[30]	Wuillemin, W.A., Velthuis, H., Lubbers, Y.T.P., de Ruig, C.P., Eldering, E. and Hack, C.E., “Potentiation of C1 inhibitor by glycosaminoglycans: Dextran sulfate species are effective inhibitors of in vitro complement activation in plasma,” J. Immunol., 159, 1953-1960, 1997.
[31]	Kirschfink, M., Blasé, L., Engelmann, S. and Schwartz-Albiez, R., “Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1,” J. Immunol., 158, 1324-1331, 1997.